138 related articles for article (PubMed ID: 35933885)
1. Incorporating progesterone receptor expression into the PREDICT breast prognostic model.
Grootes I; Keeman R; Blows FM; Milne RL; Giles GG; Swerdlow AJ; Fasching PA; Abubakar M; Andrulis IL; Anton-Culver H; Beckmann MW; Blomqvist C; Bojesen SE; Bolla MK; Bonanni B; Briceno I; Burwinkel B; Camp NJ; Castelao JE; Choi JY; Clarke CL; Couch FJ; Cox A; Cross SS; Czene K; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Ernst K; Evans DG; Figueroa JD; Fink V; Floris G; Fox S; Gabrielson M; Gago-Dominguez M; García-Sáenz JA; González-Neira A; Haeberle L; Haiman CA; Hall P; Hamann U; Harkness EF; Hartman M; Hein A; Hooning MJ; Hou MF; Howell SJ; ; ; Ito H; Jakubowska A; Janni W; John EM; Jung A; Kang D; Kristensen VN; Kwong A; Lambrechts D; Li J; Lubiński J; Manoochehri M; Margolin S; Matsuo K; Taib NAM; Mulligan AM; Nevanlinna H; Newman WG; Offit K; Osorio A; Park SK; Park-Simon TW; Patel AV; Presneau N; Pylkäs K; Rack B; Radice P; Rennert G; Romero A; Saloustros E; Sawyer EJ; Schneeweiss A; Schochter F; Schoemaker MJ; Shen CY; Shibli R; Sinn P; Tapper WJ; Tawfiq E; Teo SH; Teras LR; Torres D; Vachon CM; van Deurzen CHM; Wendt C; Williams JA; Winqvist R; Elwood M; Schmidt MK; García-Closas M; Pharoah PDP
Eur J Cancer; 2022 Sep; 173():178-193. PubMed ID: 35933885
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.
Xie Y; Li X; Wu Y; Cui W; Liu Y
World J Surg Oncol; 2022 Oct; 20(1):338. PubMed ID: 36224558
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
4. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
9. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
[TBL] [Abstract][Full Text] [Related]
10. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.
Wishart GC; Bajdik CD; Dicks E; Provenzano E; Schmidt MK; Sherman M; Greenberg DC; Green AR; Gelmon KA; Kosma VM; Olson JE; Beckmann MW; Winqvist R; Cross SS; Severi G; Huntsman D; Pylkäs K; Ellis I; Nielsen TO; Giles G; Blomqvist C; Fasching PA; Couch FJ; Rakha E; Foulkes WD; Blows FM; Bégin LR; van't Veer LJ; Southey M; Nevanlinna H; Mannermaa A; Cox A; Cheang M; Baglietto L; Caldas C; Garcia-Closas M; Pharoah PD
Br J Cancer; 2012 Aug; 107(5):800-7. PubMed ID: 22850554
[TBL] [Abstract][Full Text] [Related]
11. Negative estrogen receptors and positive progesterone receptors breast cancers.
Delvallée J; Etienne C; Arbion F; Vildé A; Body G; Ouldamer L
J Gynecol Obstet Hum Reprod; 2021 Feb; 50(2):101928. PubMed ID: 33022450
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of progesterone receptor expression in a population-based analysis.
Caldarella A; Barchielli A
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2505-2509. PubMed ID: 28889189
[TBL] [Abstract][Full Text] [Related]
13. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
14. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study.
Liu J; Gan M; Lin Z; Deng Q; Deng J; Zeng B; Shi Y; Ming J
Breast J; 2022; 2022():5469163. PubMed ID: 36531979
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.
Purdie CA; Quinlan P; Jordan LB; Ashfield A; Ogston S; Dewar JA; Thompson AM
Br J Cancer; 2014 Feb; 110(3):565-72. PubMed ID: 24300977
[TBL] [Abstract][Full Text] [Related]
17. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
20. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
